ALLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Allogene Therapeutics Inc (ALLO) does not present a strong buy opportunity for a beginner, long-term investor at this time. While there are positive catalysts such as recent analyst upgrades and promising clinical trial data, the stock's technical indicators and trading trends suggest a neutral sentiment. Additionally, the lack of recent AI trading signals and the absence of significant insider or hedge fund activity further support a cautious approach. Given the investor's preference for long-term stability, it would be prudent to monitor the stock for further developments before making an entry.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 60.67, and moving averages are converging, suggesting no strong directional trend. Key resistance levels are at 2.047 and 2.13, with support at 1.78 and 1.697.
Analyst upgrades and increased price targets following strong clinical trial data for cema-cel in large B-cell lymphoma.
Positive sentiment around the ALPHA3 trial results, which exceeded expectations.
Recent public offering of $175M, providing additional capital for operations.
Stock has declined significantly over the past year, indicating potential investor skepticism.
No recent news or significant insider/hedge fund activity.
Short-term stock trend analysis suggests a potential decline in the next week and month.
No financial data available for the latest quarter.
Analysts are generally positive, with multiple upgrades and price target increases. JPMorgan upgraded the stock to Neutral, and firms like Jefferies, Baird, and H.C. Wainwright maintain Buy or Outperform ratings with price targets ranging from $8 to $12.
